{"entity":{"id":"ci-8993","kind":"drug","name":"CI-8993","aka":["JNJ-61610588"],"tldr":"CI-8993 is an experimental monoclonal antibody from ImmuNext, in phase 1 trials for advanced solid tumours; its current status is not stated.","summary":"CI-8993 (JNJ-61610588) is a monoclonal antibody (fully human IgG1 kappa) from ImmuNext, with Curis as partner and Janssen as partner. A monoclonal antibody designed to block signalling through VISTA (V-domain Ig suppressor of T cell activation). Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in 2 studies linked below. Curis's phase 1 (NCT04475523) is completed; Curis deprioritised it in November 2022 and did not exercise its option; rights reverted to ImmuNext in January 2024 (Curis 10-K for 2023). Janssen's earlier phase 1 as JNJ-61610588 (NCT02671955) was terminated. No current development found. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"ImmuNext: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1108205/000119312520002601/d863849dex991.htm"},{"label":"ImmuNext: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820524000010/cris-20231231.htm"},{"label":"ImmuNext: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT04475523"},{"label":"ClinicalTrials.gov: trials of CI-8993","url":"https://clinicaltrials.gov/search?intr=CI-8993"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["vista"],"drugs":[],"companies":["immunext","curis","johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04475523","nct02671955"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"CI-8993","modality":"Monoclonal antibody (fully human IgG1 kappa)","mechanism":"A monoclonal antibody designed to block signalling through VISTA (V-domain Ig suppressor of T cell activation).","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ci-8993/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"vista","kind":"target","name":"VISTA","route":"/targets/vista/"}],"company":[{"id":"curis","kind":"company","name":"Curis","route":"/companies/curis/"},{"id":"immunext","kind":"company","name":"ImmuNext","route":"/companies/immunext/"},{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}],"trial":[{"id":"nct02671955","kind":"trial","name":"A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer","route":"/trials/nct02671955/"},{"id":"nct04475523","kind":"trial","name":"Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies","route":"/trials/nct04475523/"}]}}